Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec 1:1266:124738.
doi: 10.1016/j.jchromb.2025.124738. Epub 2025 Aug 15.

UHPLC-MS/MS analysis of PFAS in the serum of patients with Alzheimer's disease, mild cognitive impairment and controls: A preliminary study

O Deda  1 , S Adams  2 , M Tsolaki  3 , A Lioupi  4 , A C Tsolaki  5 , G Theodoridis  6 , I D Wilson  7 , R S Plumb  8 , H Gika  9
Affiliations
Free article

UHPLC-MS/MS analysis of PFAS in the serum of patients with Alzheimer's disease, mild cognitive impairment and controls: A preliminary study

O Deda et al. J Chromatogr B Analyt Technol Biomed Life Sci. .
Free article

Abstract

Complimentary UHPLC-MS methods for 6 ultra short chain (polar) and 30 long chain (and relatively non-polar) PFAS compounds have been developed and used to profile these compounds in human serum. The methods were developed to be rapid, with both having analysis times of ca. 5 min, to enable the rapid screening of samples. Both methods were sensitive enough to detect the target PFAS over the range 0.5-50 ng/mL. These methods were then applied to the screening of the serum of 137 subjects comprising healthy controls (HC), subjects with mild cognitive impairment (MCI) and those with Alzheimer's disease (AD). These methods demonstrated the presence of the 33 of targeted PFAS in these serum samples, presenting over a wide concentrations range with PFPrA found at the highest maximum concentration of 707 ng/mL. Interestingly the PFAS profiles found for the HC and MCI subjects differed from those of the AD patients. The reason(s) for differences in the PFAS profiles obtained for serum from AD patients compared to HC/MCI subjects is unclear and may be unrelated to disease but clearly warrants further investigation to clarify the underlying reasons for this observation.

Keywords: Exposomics; Exposure; Long chain PFAS; Screening; UHPLC-MS/MS; Ultra short chain PFAS.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: O. Deda, M. Tsolaki, A. Lioupi, G. Theodoridis, and H. Gika report financial support provided by Horizon Europe. O. Deda, G. Theodoridis, H. Gika, A. Lioupi, and M. Tsolaki report a relationship with the Aristotle University of Thessaloniki Special Account for Research Funds that includes employment. S. Adams is a former employee of Waters Corp., and R.S. Plumb is an employee of Waters Corp. I.D. Wilson has in the past acted as a paid consultant to Waters and a number of other companies. The other authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. G. Theodoridis and I.D. Wilson are editors of the Journal of Chromatography B; to avoid conflicts of interest, the peer review of this article was managed independently by another editor and handled according to standard procedures.

LinkOut - more resources